Biogen To Buy Reata Pharma In Around $7.3 Bln Deal; Stocks Move In Premarket

Biotechnology company Biogen Inc. (BIIB) Friday announced its agreement to acquire Reata Pharmaceuticals, Inc. (RETA) for $172.50 per share in cash, reflecting an enterprise value of around $7.3 billion.

from RTT - Before the Bell https://ift.tt/KkZRHAf
via IFTTT